Inflammatory Bowel Disease

Share on facebook
Share on pinterest
Share on twitter
Share on email
Share on whatsapp

Medical cannabis for inflammatory bowel disease: real-life experience of mode of consumption and assessment of side-effects.

Eur J Gastroenterol Hepatol 2019

Timna Naftali 1 2, Lihi Bar-Lev Schleider 3, Fabiana Sklerovsky Benjaminov 1 2, Ido Lish 1 2, Fred M Konikoff 1 2, Yehuda Ringel 1 2

1Meir Medical Center Institute of Gastroenterology and Hepatology, Kfar Saba; 2Sackler School of Medicine, Tel Aviv University, Tel Aviv; 3Soroka University Medical Centre and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheba, Israel.

Inflammatory bowel diseases (mainly Crohn’s and colitis) are chronic, debilitating, non-infectious, inflammatory diseases of the digestive tract. Conventional treatment consists of anti-inflammatory and immunomodulating drugs. However, the rate of response to currently available treatments is limited to 40–60%, and many patients remain symptomatic despite maximal medical treatment. This study, conducted in collaboration with the Gastroenterology Unit at Meir Medical Center, is a large-scale, long-term study that included data on patients licensed to treat medical cannabis with inflammatory bowel disease to determine the effect of cannabis on disease symptoms on long-term treatment as well as side effects. Most patients reported significant improvement in their symptoms and the use of other medications after 1 year of cannabis consumption was significantly reduced.

STUDY POPULATION: 127 Crohn’s and colitis patients who received a license for use of medical cannabis (86 males, mean age 39.6).

STUDY PRODUCT: Half of the patients in the study received the company’s products regularly.

RESULTS:  

• During the study period, 127 patients received a license to use medical cannabis and entered the study.

General improvement – the average Harvey-Bradshaw index, which measures the severity of the disease, improved from 14.0 to 7.0 (P <0.001).

Weight gain – During follow-up of 3.6 years (median 44 months), there was a slight but statistically significant weight gain of 2 kg.

Decrease in drug consumption – the need for other medications was significantly reduced.

Improve in employment rates – employment among patients increased from 65% to 74%.

• From the study it can be concluded that most Crohn’s and colitis patients using cannabis are satisfied with a dose of 30 gram per month.

• No negative effects of cannabis use were observed on the patients’ social or occupational status.

• The side effects described by the patients were mild. The most common were dry mouth (63%), memory decline (34%), eye irritation (14%), dizziness, (13%) confusion (9%), and restlessness (8%).

FULL STUDY

Have you liked our facebook page?

Common Questions

Search by Keyword

Recent publications

Ordering Tikun Olam Products

Proudly leading the revolution for modern Cannabis treatment

Related Topics

Epidemiological Characteristics, Safety and Efficacy of Medical Cannabis in the Elderly European Journal of Internal Medicine, 2018 Ran Abuhasira1, Lihi Bar-Lev Schleider1,2, Raphael Mechoulam3, Victor

Overcoming the Bell‐Shaped Dose‐Response of Cannabidiol by Using Cannabis Extract Enriched in CannabidiolPharmacology & Pharmacy, 2015 Ruth Gallily1, Zhannah Yekhtin1, Lumír Ondřej Hanuš2 1The Lautenberg

Avidekel Cannabis extracts and cannabidiol are as efficient as Copaxone in suppressing EAE in SJL/J mice Inflammopharmacology 2018 Ruth Gallily1, Zhannah Yekhtin1 1The Lautenberg Center